Previous 10 | Next 10 |
Fireside Chat with BTIG Research Scheduled for November 29, 2022 at 12:00pm Eastern Panel Hosted by Cantor Research Scheduled for December 8, 2022 at 1:45pm Eastern Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that its partner Genentech , a member of the Roche Group, has launched a Phase 2a, multicenter...
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants ...
Lineage Cell Therapeutics press release ( NYSE: LCTX ): Q3 GAAP EPS of -$0.04. Revenue of $3M (+32.2% Y/Y). Cash, cash equivalents, and marketable securities totaled $66.4M as of September 30, 2022, which is expected to support planned operations into Q3 2024. Fo...
Lineage Cell Therapeutics ( NYSE: LCTX ) said on Monday the United States Patent and Trademark Office had issued a patent for the company's application with claims covering manufacturing processes for its oligodendrocyte progenitor cell therapy candidate (OPC1) for th...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a...
Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Alliance for Reg...
Expansions Expected to Support Process Development and Production of Current and Future Cell Transplant Programs Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth comp...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...